Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives Consensus Recommendation of "Buy" from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) have received a consensus recommendation of "Buy" from the five research firms that are covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $37.25.

ELVN has been the topic of a number of recent research reports. Jones Trading decreased their target price on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a research report on Friday, May 16th. HC Wainwright raised their price target on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, May 15th.

Insiders Place Their Bets

In related news, COO Anish Patel sold 6,667 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $21.44, for a total value of $142,940.48. Following the completion of the transaction, the chief operating officer now owns 323,310 shares in the company, valued at $6,931,766.40. The trade was a 2.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction on Thursday, February 27th. The stock was sold at an average price of $20.41, for a total value of $66,332.50. Following the sale, the chief financial officer now directly owns 13,000 shares of the company's stock, valued at approximately $265,330. This trade represents a 20.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 86,111 shares of company stock worth $1,657,145 over the last quarter. Company insiders own 29.20% of the company's stock.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its holdings in shares of Enliven Therapeutics by 230.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,598 shares of the company's stock valued at $36,000 after purchasing an additional 1,114 shares during the period. GAMMA Investing LLC grew its position in shares of Enliven Therapeutics by 3,058.1% during the 1st quarter. GAMMA Investing LLC now owns 2,716 shares of the company's stock worth $53,000 after purchasing an additional 2,630 shares in the last quarter. Quantbot Technologies LP acquired a new position in shares of Enliven Therapeutics during the 1st quarter worth approximately $60,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $97,000. Finally, BNP Paribas Financial Markets acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $112,000. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Stock Down 0.7%

ELVN stock traded down $0.11 during mid-day trading on Thursday, reaching $16.29. 87,926 shares of the stock traded hands, compared to its average volume of 259,293. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $30.03. The business has a 50-day moving average of $18.37 and a two-hundred day moving average of $21.16. The firm has a market capitalization of $799.48 million, a PE ratio of -8.53 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.06). On average, equities research analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.